President Obama has unveiled a new initiative to develop prevention and treatment strategies based on each person's genes, environment and lifestyle.
Tox21 is a collaborative effort to improve methods scientists use to evaluate potential toxicity of environmental chemicals and medicines.
Read about how NIH and its partners are advancing treatments for rare lipid disorders, activities planned for NIH's Rare Disease Day, improving CTSA-funded research protocols, and more.
NIH researchers are collaborating with Vtesse, Inc., to develop treatments for Niemann-Pick disease type C and other rare lysosomal storage disorders.
How is NCATS advancing translational research? Learn more about the Center's work and some of its early successes.
MORE CENTER NEWS
NCATS screening technologies enable identification of potential treatment target for neurological disorder.
Research team identifies 50+ drugs that may block Ebola infection.
- US Lawmakers Seek to Revamp Biomedical Research January 28 • Nature
- 4 Things You Need to Know about the Sweeping FDA Reform Bill Congress Proposed Last Night • BioPharma Dive
- CTRI Expands On-site Biostatistics Services to Rady Children's Hospital • University of California San Diego
- More News & Events...